Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses elexacaftor-tezacaftor-ivacaftor plus ivacaftor (Trikafta) Aged 2 to 5 years elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg (granules) plus ivacaftor 75 mg (granules) elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg (granules) plus ivacaftor 59.5 mg (granules), oral Aged 6 years and older 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor (combination tablet) plus 75 mg ivacaftor (tablet), oral 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor (combination tablet) plus 150 mg ivacaftor (tablet), oral. Indication: For the treatment of cystic fibrosis in patients aged 2 years and older who have at least 1 F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data.